Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Anteris Technologies Global Corp. Common Stock (AVR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: AVR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16.5
1 Year Target Price $16.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.32% | Avg. Invested days 8 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 156.14M USD | Price to earnings Ratio - | 1Y Target Price 16.5 |
Price to earnings Ratio - | 1Y Target Price 16.5 | ||
Volume (30-day avg) 4 | Beta 0.41 | 52 Weeks Range 2.34 - 8.79 | Updated Date 12/16/2025 |
52 Weeks Range 2.34 - 8.79 | Updated Date 12/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3379.29% |
Management Effectiveness
Return on Assets (TTM) -184.05% | Return on Equity (TTM) -618.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 217758756 | Price to Sales(TTM) 105.35 |
Enterprise Value 217758756 | Price to Sales(TTM) 105.35 | ||
Enterprise Value to Revenue 101.8 | Enterprise Value to EBITDA - | Shares Outstanding 41197570 | Shares Floating 31072780 |
Shares Outstanding 41197570 | Shares Floating 31072780 | ||
Percent Insiders 0.2 | Percent Institutions 46.75 |
Upturn AI SWOT
Anteris Technologies Global Corp. Common Stock
Company Overview
History and Background
Anteris Technologies Global Corp. is a global medical device company focused on developing and commercializing innovative cardiovascular solutions. The company was founded with a vision to address unmet needs in the treatment of structural heart disease. Significant milestones include the development and advancement of its proprietary DurAVu00ae valve technology and its subsequent clinical trials and regulatory pathways.
Core Business Areas
- Cardiovascular Solutions: Anteris Technologies focuses on the design, development, and commercialization of novel medical devices for the treatment of cardiovascular diseases, with a particular emphasis on structural heart interventions.
Leadership and Structure
Anteris Technologies Global Corp. is led by a management team with extensive experience in the medical device industry. The organizational structure is designed to support research and development, clinical trials, regulatory affairs, manufacturing, and commercialization efforts.
Top Products and Market Share
Key Offerings
- DurAVu00ae Valve: The DurAVu00ae valve is a novel, balloon-expandable transcatheter aortic valve replacement (TAVR) system designed to offer improved durability and performance. It is composed of a bovine pericardial tissue and a unique biopolymer-based annulus. Market share data is not yet established as it is in its developmental and clinical trial phases. Key competitors in the TAVR market include Edwards Lifesciences (Sapien), Medtronic (Evolut), Abbott (Portico), and Boston Scientific (ACURATE).
Market Dynamics
Industry Overview
The structural heart disease market, particularly TAVR, is a rapidly growing segment within the broader cardiovascular medical device industry. It is characterized by technological innovation, increasing patient demand for minimally invasive procedures, and a competitive landscape with established players and emerging technologies.
Positioning
Anteris Technologies is positioning itself as an innovator in the TAVR space with its DurAVu00ae valve technology, aiming to offer a differentiated solution in terms of durability and patient outcomes. Its competitive advantages lie in its proprietary materials and design, which may offer enhanced performance compared to existing technologies.
Total Addressable Market (TAM)
The global TAVR market is a significant and growing segment of the cardiovascular device market, with projections indicating substantial expansion over the next decade due to an aging population and increasing adoption of minimally invasive procedures. Anteris Technologies is aiming to capture a portion of this TAM with its innovative valve technology.
Upturn SWOT Analysis
Strengths
- Proprietary DurAVu00ae valve technology with potential for improved durability.
- Experienced management team in the medical device sector.
- Focus on a high-growth segment of the cardiovascular market.
- Potential for reduced calcification and improved hemodynamic performance.
Weaknesses
- Limited clinical data and market penetration compared to established players.
- Reliance on ongoing clinical trials and regulatory approvals.
- Significant capital investment required for R&D and commercialization.
- Brand recognition is still developing.
Opportunities
- Growing demand for minimally invasive cardiovascular procedures.
- Expansion into new geographic markets post-regulatory approval.
- Potential for next-generation valve designs and indications.
- Partnerships with leading cardiovascular centers and physicians.
Threats
- Intense competition from established medical device companies.
- Potential for new disruptive technologies to emerge.
- Stringent regulatory approval processes and timelines.
- Reimbursement challenges and healthcare policy changes.
Competitors and Market Share
Key Competitors
- Edwards Lifesciences (EW) - Sapien TAVR System
- Medtronic plc (MDT) - Evolut TAVR System
- Abbott Laboratories (ABT) - Portico TAVR System
- Boston Scientific Corporation (BSX) - ACURATE TAVR System
Competitive Landscape
Anteris Technologies faces a highly competitive landscape dominated by large, established medical device companies with significant market share, extensive sales forces, and broad product portfolios. Its advantage must stem from superior technology and clinical performance to gain traction and market share.
Growth Trajectory and Initiatives
Historical Growth: Historically, Anteris Technologies has experienced growth in its operational capacity and R&D advancements, evidenced by the progression of its DurAVu00ae valve through clinical trials. Financial growth is primarily driven by capital raises to fund its development pipeline.
Future Projections: Future growth projections are contingent upon successful clinical trial outcomes, regulatory approvals, and the effective commercialization of its DurAVu00ae valve technology in the TAVR market. Analyst projections would focus on potential market penetration and revenue generation post-launch.
Recent Initiatives: Recent initiatives likely involve advancing clinical trials for the DurAVu00ae valve, seeking regulatory approvals in key markets, and potentially building out its commercial infrastructure in anticipation of product launch.
Summary
Anteris Technologies is a promising medical device company focused on innovating in the structural heart disease market, particularly TAVR. Its DurAVu00ae valve technology presents a potential differentiator. However, it faces significant competition from established players and relies heavily on successful clinical trials and regulatory approvals to achieve its growth potential. Managing capital effectively and demonstrating clear clinical advantages will be crucial for its success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations (where available)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Industry Analysis Reports (general market trends)
- SEC Filings (for publicly available financial data)
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The data presented is based on publicly available information and general industry knowledge, and may be subject to change. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anteris Technologies Global Corp. Common Stock
Exchange NASDAQ | Headquaters Toowong, QLD, Australia | ||
IPO Launch date 2024-12-13 | Vice Chairman & CEO Mr. Wayne Geoffrey Paterson | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 136 | Website https://anteristech.com |
Full time employees 136 | Website https://anteristech.com | ||
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.